FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198774415> ?p ?o ?g. }

• W3198774415 endingPage "e1559" @default.
• W3198774415 startingPage "e1546" @default.
• W3198774415 abstract "Background and Objectives To report safety of ocrelizumab (OCR) up to 7 years in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) enrolled in clinical trials or treated in real-world postmarketing settings. Methods Safety analyses are based on integrated clinical and laboratory data for all patients who received OCR in 11 clinical trials, including the controlled treatment and open-label extension (OLE) periods of the phase 2 and 3 trials, plus the phase 3b trials VELOCE, CHORDS, CASTING, OBOE, ENSEMBLE, CONSONANCE, and LIBERTO. For selected adverse events (AEs), additional postmarketing data were used. Incidence rates of serious infections (SIs) and malignancies were contextualized using multiple epidemiologic sources. Results At data cutoff (January 2020), 5,680 patients with multiple sclerosis (MS) received OCR (18,218 patient-years [PY] of exposure) in clinical trials. Rates per 100 PY (95% confidence interval) of AEs (248; 246–251), serious AEs (7.3; 7.0–7.7), infusion-related reactions (25.9; 25.1–26.6), and infections (76.2; 74.9–77.4) were similar to those within the controlled treatment period of the phase 3 trials. Rates of the most common serious AEs, including SIs (2.01; 1.81–2.23) and malignancies (0.46; 0.37–0.57), were consistent with the ranges reported in epidemiologic data. Discussion Continuous administration of OCR for up to 7 years in clinical trials, as well as its broader use for more than 3 years in the real-world setting, are associated with a favorable and manageable safety profile, without emerging safety concerns, in a heterogeneous MS population. Classification of Evidence This analysis provides Class III evidence that long-term, continuous treatment with OCR has a consistent and favorable safety profile in patients with RMS and PPMS. This study is rated Class III because of the use of OLE data and historical controls." @default.
• W3198774415 created "2021-09-13" @default.
• W3198774415 creator A5013431844 @default.
• W3198774415 creator A5025472260 @default.
• W3198774415 creator A5031171090 @default.
• W3198774415 creator A5039001065 @default.
• W3198774415 creator A5049256623 @default.
• W3198774415 creator A5054249700 @default.
• W3198774415 creator A5054874316 @default.
• W3198774415 creator A5062770573 @default.
• W3198774415 creator A5071219650 @default.
• W3198774415 creator A5071976849 @default.
• W3198774415 creator A5076338840 @default.
• W3198774415 date "2021-09-02" @default.
• W3198774415 modified "2023-10-16" @default.
• W3198774415 title "Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis" @default.
• W3198774415 cites W1675831178 @default.
• W3198774415 cites W1731046649 @default.
• W3198774415 cites W1928083905 @default.
• W3198774415 cites W2028485353 @default.
• W3198774415 cites W2042725832 @default.
• W3198774415 cites W2073728662 @default.
• W3198774415 cites W2094502152 @default.
• W3198774415 cites W2096518250 @default.
• W3198774415 cites W2105167551 @default.
• W3198774415 cites W2116016714 @default.
• W3198774415 cites W2126975968 @default.
• W3198774415 cites W2155533563 @default.
• W3198774415 cites W2155835718 @default.
• W3198774415 cites W2263703605 @default.
• W3198774415 cites W2344473058 @default.
• W3198774415 cites W2489481562 @default.
• W3198774415 cites W2561881161 @default.
• W3198774415 cites W2565433170 @default.
• W3198774415 cites W2579133420 @default.
• W3198774415 cites W2798039679 @default.
• W3198774415 cites W2804318011 @default.
• W3198774415 cites W2905167999 @default.
• W3198774415 cites W2908395900 @default.
• W3198774415 cites W2912026765 @default.
• W3198774415 cites W2967124351 @default.
• W3198774415 cites W2970828189 @default.
• W3198774415 cites W2977883158 @default.
• W3198774415 cites W3004739468 @default.
• W3198774415 cites W3008771651 @default.
• W3198774415 cites W3011073921 @default.
• W3198774415 cites W3045017175 @default.
• W3198774415 cites W3045825841 @default.
• W3198774415 cites W3047302551 @default.
• W3198774415 cites W3047304708 @default.
• W3198774415 cites W3075947290 @default.
• W3198774415 cites W3088332612 @default.
• W3198774415 cites W3194648640 @default.
• W3198774415 doi "https://doi.org/10.1212/wnl.0000000000012700" @default.
• W3198774415 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8548959" @default.
• W3198774415 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34475123" @default.
• W3198774415 hasPublicationYear "2021" @default.
• W3198774415 type Work @default.
• W3198774415 sameAs 3198774415 @default.
• W3198774415 citedByCount "57" @default.
• W3198774415 countsByYear W31987744152018 @default.
• W3198774415 countsByYear W31987744152021 @default.
• W3198774415 countsByYear W31987744152022 @default.
• W3198774415 countsByYear W31987744152023 @default.
• W3198774415 crossrefType "journal-article" @default.
• W3198774415 hasAuthorship W3198774415A5013431844 @default.
• W3198774415 hasAuthorship W3198774415A5025472260 @default.
• W3198774415 hasAuthorship W3198774415A5031171090 @default.
• W3198774415 hasAuthorship W3198774415A5039001065 @default.
• W3198774415 hasAuthorship W3198774415A5049256623 @default.
• W3198774415 hasAuthorship W3198774415A5054249700 @default.
• W3198774415 hasAuthorship W3198774415A5054874316 @default.
• W3198774415 hasAuthorship W3198774415A5062770573 @default.
• W3198774415 hasAuthorship W3198774415A5071219650 @default.
• W3198774415 hasAuthorship W3198774415A5071976849 @default.
• W3198774415 hasAuthorship W3198774415A5076338840 @default.
• W3198774415 hasBestOaLocation W31987744151 @default.
• W3198774415 hasConcept C126322002 @default.
• W3198774415 hasConcept C187212893 @default.
• W3198774415 hasConcept C197636746 @default.
• W3198774415 hasConcept C197934379 @default.
• W3198774415 hasConcept C203014093 @default.
• W3198774415 hasConcept C2777054765 @default.
• W3198774415 hasConcept C2778843634 @default.
• W3198774415 hasConcept C2779338263 @default.
• W3198774415 hasConcept C2780640218 @default.
• W3198774415 hasConcept C2780653079 @default.
• W3198774415 hasConcept C535046627 @default.
• W3198774415 hasConcept C71924100 @default.
• W3198774415 hasConceptScore W3198774415C126322002 @default.
• W3198774415 hasConceptScore W3198774415C187212893 @default.
• W3198774415 hasConceptScore W3198774415C197636746 @default.
• W3198774415 hasConceptScore W3198774415C197934379 @default.
• W3198774415 hasConceptScore W3198774415C203014093 @default.
• W3198774415 hasConceptScore W3198774415C2777054765 @default.
• W3198774415 hasConceptScore W3198774415C2778843634 @default.
• W3198774415 hasConceptScore W3198774415C2779338263 @default.
• W3198774415 hasConceptScore W3198774415C2780640218 @default.

• next